Hepatitis C Market Size, Share, and Trends 2026 to 2035

Revenue, 2025

USD 8.16 Bn

Forecast Year, 2035

USD 10.95 Bn

CAGR, 2026 - 2035

2.98%

Report Coverage

Global

What is the Hepatitis C Market Size?

The global hepatitis C market size is calculated at USD 8.16 billion in 2025 and is predicted to increase from USD 8.38 billion in 2026 to approximately USD 10.95 billion by 2035, expanding at a CAGR of 2.98% from 2026 to 2035.

Hepatitis C Market Key Takeaways

• North America led the global market with the highest market share in 2025.
• Asia Pacific region is estimated to expand the fastest CAGR between 2026 and 2035.
• By distribution channel, the hospital & retail pharmacies segment residential the biggest market share in 2025.

Market Overview

A viral infection called hepatitis C can result in severe liver damage by inflaming the liver. Contaminated blood can transmit the hepatitis C virus (HCV). Hepatitis C treatment up until recently needed weekly injections and oral medications, both of which were difficult for many HCV-infected individuals to take due to other health issues or unfavorable side effects. Furthermore, oral medications taken consistently for two to six months can typically treat chronic HCV.

Nevertheless, about half of those who have HCV are unaware of their infection, primarily because they don't exhibit any signs, which can take years to manifest. Because of this, even people without symptoms or known liver disease should be screened for hepatitis C, according to the U.S. Preventive Services Task Force. All people born between 1945 and 1965 are the most at risk because they are five times more likely to contract the disease than people born in other years.

Hepatitis C Market Growth Factors

The market will expand as a result of factors including the expansion of the pharmaceutical industry, an aging population, rising healthcare costs, urbanization improving monitoring and screening methods, and a rise in liver cancer and cirrhosis deaths brought on by HBV. Rigid competition, management issues, a lack of diagnostic resources, the high expense of medical care, and legal restrictions, on the other hand, would pose a threat to the market's expansion. Growth in pharmaceutical research and development, cooperation, innovation, and research, high demand for biomarker based tests, HBV treatments under development, government efforts, and increased public awareness are a few noteworthy trends that may be observed.

• The market for treating Hepatitis C is expected to be driven by increased awareness and the development of new medications
• Drugs' effectiveness in curing hepatitis C will fuel demand globally
• Research and development efforts have advanced
• Increasing new drug clearances for hepatitis and rising new drug releases
• Increasing prevalence of viral Hepatitis C
• Government support that is favorable for raising awareness of hepatitis
• Increasing incidence of chronic illnesses

Market Scope

Market Dynamics

Key Market Drivers

• Drugs' effectiveness in curing hepatitis C will fuel demand globally - Additionally, a sizable patient population has acute hepatitis C, the other hepatitis C viral variant. The steady and drastic revenue erosion of major market leaders like Gilead, as well as the expected generic introduction by Gilead, are, however, factors limiting the growth of hepatitis C drugs in the global market. Despite these discouraging elements, a number of significant market players are engaged in the creation and promotion of Hepatitis C therapeutics.
• The Hepatitis C market is most likely to be driven by increased awareness and the development of new drugs - Hepatitis C affects a sizable patient population worldwide, but at the same time, shifting patient patterns are resulting in a marked decline in patients. Because hepatitis C medications have high cure rates, their superior therapeutic efficacy has resulted in a significant decrease in the patient community. The Centers for Disease Control and Prevention (CDC) predict that 3.5 million Americans were living with chronic hepatitis C in 2020.
• Government programs to raise knowledge of hepatitis and how to treat it - Hepatitis C is extremely prevalent and can cause serious liver cirrhosis, which can be fatal. Furthermore, it is anticipated that over the course of the forecast period, government initiatives to raise awareness about hepatitis and its treatment will spur market development. For instance, a virtual gathering called the "World Hepatitis Summit (WHS)" took place in June 2022. The World Health Organization co-sponsored the World Hepatitis Summit 2022. (WHO). The summit offers a venue for the large hepatitis community to assess current development and exchange thoughts, stories, and best practices for overcoming the many difficulties associated with viral hepatitis.

Key Market Challenges

• The cost of hepatitis treatments is high - The market for hepatitis medications is predicted to grow slowly over the anticipated period due to the high capital needed for hepatitis pharmaceutical production. Because they are made from expensive basic materials like active pharmaceutical ingredients (APIs) and pharmacological intermediates, hepatitis medications are expensive. Since skilled labor is needed, the intricate process of producing, separating, and utilizing raw materials for the creation of pharmaceutical and biopharmaceutical treatments raises the price of medications overall.

Key Market Opportunities

Increasing awareness creates opportunities - In contrast to other established nations, developing nations like India, China, and Brazil have a sizable patient pool. This raises the demand for medications used to treat hepatitis C. Few nations and state governments have taken steps to reduce the spread of hepatitis C by providing special funding for programs that treat the illness or by subsidizing certain medications. Several private NGOs raise public consciousness of the hepatitis C infection and educate the populace about it. These could also be viewed as market factors for hepatitis C medications. Hepatitis C infection is becoming more common among the world's populace. Sharp needles, unkempt me d ical supplies , and blood transfers from an infected mother to a newborn baby are the main causes of this.

Segment Insights

Drugs Class Insights

On the basis of drug class it is classified into HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NSSA Inhibitors, Combination Therapy, Interferon and Antiviral, Peginterferon alfa 2a, Peginterferon alfa 2b, Ribavirin and Others. About one-third of patients who have hepatitis C develop cirrhosis of the liver, some of whom will later develop liver failure or liver cancer. Hepatitis C is a significant cause of liver disease in the United States. Currently, a combination therapy such as alpha interferon and ribavirin administered for 6 to 12 months is the suggested treatment for hepatitis C.

Oral antiviral medication is called ribavirin. Both an immune system booster and an antiviral, interferon must be administered intravenously (three times per week) and comes with a long list of unpleasant side effects. The duration of the drug treatment is expected to be between 6 and 12 months.

Distribution Channel Insights

The segment of hospital & retail pharmacies had the largest revenue share. The hospital and retail pharmacies sector is predicted to have the highest income in 2025 and to dominate the market throughout the projection period. The significant market share can be attributed to the numerous patients who seek hepatitis C diagnosis and treatment immediately at the hospital. In addition, the sector is anticipated to have significant growth opportunities due to the rising number of hospital & retail pharmacies providing hepatitis C treatments in emerging economies.

Regional Insights

North America, Europe, and Asia Pacific are the three regions that primarily control the global hepatitis C industry. The North American market had the highest revenue in 2024, primarily because of the U.S.'s high demand, the patient population's comparatively higher affordability, and the region's awareness of advanced therapeutics. Some of the key elements influencing the high share include the availability of a well-developed healthcare system, reimbursement, and access to the most cutting-edge medications. Over the course of the projection period, the Asia Pacific market is anticipated to expand at the fastest rate.

The region's growth prospects are anticipated to be favorably reinforced by the high disease burden, expanding access to medicines, improvements in healthcare and sanitation, and increasing awareness of the hepatitis vaccination. To make it easier for more people to access high-quality healthcare, nations like India, China, Indonesia, and other South Asian economies are constantly raising their healthcare spending and reimbursement coverage.

U.S. Market Trends

In the U.S. market, there is a declining overall prevalence and an increase in acute infections in younger adults as a result of injection drug use. Access to treatment disparities exist even though curative DAAs are available. An increase in universal screening of adults is increasing diagnosis rates and aiding in finding out chronic infections at an earlier stage.

Additionally, it is expected that the Asia Pacific region will benefit from the rising demand for generic medications. Gilead has granted permission to seven Indian manufacturers to export some of the hepatitis medicines to various nations. More than half of the people who have HCV infection live in the nations that are included in this agreement.

India Market Trends

The hepatitis C burden in India is high, and a massive screening and treatment initiative is needed. Programs such as NVHCP by the government are helping in decentralized care that provides free testing and treatment. Special treatment in regions at high risk, particularly for individuals injecting drugs, is very important in minimizing the prevalence of infections.

Transforming Care Through Antiviral Advancements in Europe

Europe shows a significant growth in the hepatitis C industry during the forecast period. It is essential to handle evolving viral threats, improve patient results, and guarantee the sustainability of healthcare systems in the face of rising pandemic risks. Advancements are vital for enhancing the treatment of chronic infections, like hepatitis C, hepatitis B, and herpesviruses, where vaccines have thus far failed or are not available. Modern treatments aim to reduce virus load, prevent hospitalization, and even decrease disease severity, mainly for immunocompromised patients.

Germany Market Trends

Germany focuses on the combination of care and the high availability of DAAs with high success rates of treatment. Routine health check-ups are screening programs that help in early diagnosis. Greater emphasis on high-risk groups, especially in prisons, can be used to serve any gaps in access to treatment and enhance disease management outcomes.

Strategic Insights and Growth Opportunities in Latin America

Latin America shows a notable growth in the hepatitis C industry during the forecast period. It is driven by a convergence of global supply chain reconfiguration, a dominant role in the energy transition, and rapid digital transformation. Growing global need for food security places Latin America of the world's arable land, in a major position.

Brazil Market Trends

Through its public health system, Brazil offers universal access to treatment of hepatitis C, but with regional differences. The target is the older population, and the increase in cases in the younger population is being tracked. Enhancing national surveillance mechanisms enhances monitoring of the trend of infections and facilitates better responses to the health issue.

Chronic Hepatitis C Treatment Industry in MEA

MEA shows a rapid growth in the hepatitis C industry during the forecast period. It is driven by a high prevalence of infections, which thus necessitates widespread, effective care. The region has a high prevalence of chronic HCV, usually driven by historic unsafe medical practices, even creating a vast population in demand of care. The availability of affordable generic DAAs has enhanced access in developing nations, thus making it possible to treat larger populations compared to high-expense branded therapies.

Saudi Arabia Market Trends

The introduction of mandatory hepatitis C screening and increased access to DAA have helped Saudi Arabia to reduce the incidence of hepatitis C significantly. Specific initiatives aim at high-risk populations (e.g., older adults and hemodialysis patients). Although the success of treatments is high, there are still issues with providing equal access in rural and underserved areas.

Hepatitis C Market Companies

• AbbVie: AbbVie provides a strong portfolio for the Hepatitis C market, thus centered on the pan-genotypic, direct-acting antiviral Mavyret, programmed to cure HCV in as few as eight weeks. Mavyret treats all six major genotypes, thus making it a highly efficient treatment alternative that has secured a significant market share.
• Kadmon Holdings Inc.: Kadmon Holdings Inc. provides products and services for the treatment and management of chronic hepatitis C, mainly through its acquisition of Three Rivers Pharmaceuticals.
• F. Hoffmann-La Roche Ltd.: F. Hoffmann-La Roche Ltd. is a vast player in the Hepatitis C market, aiming heavily on advanced molecular diagnostics, screening, and even monitoring solutions rather than current direct-acting antiviral treatments.

Other Major Key Players

• Bristol-Myers Squibb Company
• Gilead Sciences, Inc.
• GlaxoSmithKline
• J & J
• Lupin Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Teva Pharmaceuticals
• Zydus Pharmaceuticals

Segments Covered in the Report

By Drug Class

• HCV Protease Inhibitors
• HCV Polymerase Inhibitors
• HCV NSSA Inhibitors
• Combination Therapy
  • Ledipasvir & Sofosbuvir
  • Ombitasvir, Paritaprevir, Ritonavir & Dasabuvir
  • Elbasvir & Grazoprevir
  • Others
• Interferon and Antiviral
• Peginterferon alfa 2a
• Peginterferon alfa 2b
• Ribavirin
• Others

By Distribution Channel

• Hospital & Retail Pharmacies
• Online Pharmacies

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa